NCT05146219已完成2 期
A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal Metastases
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- Extracranial Overall Response Rate (eORR)
研究概览
简要总结
To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.
详细描述
This is an open label, multi-center phase II study to evaluate the efficacy and safety in EGFR mutated NSCLC patients with brain or leptomeningeal metastases. The patients will be assigned to the appropriate treatment cohorts based on the criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with non-small cell lung cancer (NSCLC) by histology or cytology, and with brain and leptomeningeal metastases. For LM patients, the diagnosis of leptomeningeal metastasis requires detection of cancer cell or EGFR mutation in the CSF.
- •Presence of an activating EGFR-sensitive mutations (including exon 19 deletions, L858R, the above mentioned mutations alone or co-existed with other EGFR-mutated sites). A positive T790M mutation is required for patients who have progressed following prior 1/2 generation EGFR-TKI therapy.
- •Stable brain/leptomeningeal metastases that do not require immediate or planned local treatment for it during the study period.
- •Presence of intracranial and extracranial measurable lesions without local treatment at the same time.
- •The ECOG score is 0-2 (including 0 and 2), and there is no deterioration 2 weeks before the study, and the expected survival is not less than 3 months.
- •Adequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
- •Absolute neutrophil count ≥1.5×109/L and white blood cell count ≥3×109/L;
- •Platelet count ≥100×109/L;
- •Hemoglobin ≥90g/L;
- •Serum creatinine ≤1.5× upper normal limit (ULN) and creatinine clearance ≥50 mL/min (calculated according to the Cockcroft and Gault formula);
- •AST and ALT≤2.5×ULN if no confirmed liver metastasis; AST, ALT≤5×ULN if confirmed liver metastasis;
- •Total bilirubin ≤1.5×ULN in the absence of proven liver metastasis; total bilirubin ≤3×ULN in patients with proven liver metastasis or Gilbert syndrome (hyperindirect bilirubinemia);
- •International standardized ratio (INR) ≤1.5, and activated partial prothrombin time (APTT) ≤1.5×ULN.
- •Male patients and female patients of reproductive age should take adequate contraceptive measures from signing informed consent to 3 months after the last study drug treatment; Women of childbearing age have negative pregnancy test results within 7 days of the first dose.
- •Patients having recovered from all grade ≤ 1 toxicities related to previous anticancer therapies (CTCAE v 5.0) except for alopecia, platinum-therapy-related neuropathy (where ≤2 is allowed) before first dose of study treatment.
- •Patients can understand and voluntarily sign the informed consent form.
- •Patient able to comply with study requirements.
排除标准
- •Any of the following treatment:
- •Previous treatment with 3rd generation EGFR inhibitor (Osimertinib, Almonertinib, Furmonertinib, etc.)；
- •The time from the treatment of reversible EGFR-TKI (e.g., Gefitinib, Erlotinib, Icotinib) to the first administration of the drug in this study did not exceed 8 days or 5 half-lives (whichever is longer); the time from the treatment of irreversible EGFR-tkis (e.g., Afatinib, Dacomitinib, Neratinib, etc.) do not exceed 14 days or 5 half-lives (whichever is longer)；
- •Previous treatment with Systematic antitumor therapy, including standard chemotherapy, biotherapy and immunodrug therapy within 28 days before the first dose of the study drug, and traditional Chinese medicine antitumor therapy within 7 days before the first dose of the study drug.
- •Receiving radiation to more than 30% of the bone marrow or with a wide field of radiation that had to be completed within 28 days of the first dose of study treatment; Radiotherapy with a limited field of radiation within 7 days of the first dose of study treatment or palliative radiation therapy for bone metastasis;
- •Previous treatment with whole brain radiotherapy (WBRT). Patients who have previously received stereotactic radiotherapy (SRT) or other CNS local treatments (such as intrathecal chemotherapy) can be enrolled if the time from the completion of treatment to the initial study medication is more than 2 weeks;
- •Uncontrollable pleural and abdominal effusion. For patients with pleural effusion, pleural effusion should be stabilized for 2 weeks prior to initial medication (diuretics, pleural effusion or pleural infusion are not allowed during this period);
- •Major surgery within 4 weeks of the first dose of study treatment;
- •Patients currently receiving (or at least within 14 days prior to receiving the first dose )medications or herbal supplements known to be potent inhibitors or inducers of cytochrome P450 isoenzyme (CYP)3A
- •Patients who are receiving and need to continue receiving medications during the study that are known to prolong the QTc interval or may cause tachycardia;
- •Participants in other clinical trials (other than non-interventional clinical trials) within 28 days prior to the first administration of the investigational drug.
- •Patients with leptomeningeal metastases (LM) who cannot be examined with enhanced MRI. Presence of leptomeningeal metastases only.
- •Patients with CNS complications requiring emergency neurosurgical treatment (e.g. surgery, etc.). Patients with CNS symptoms should be controlled by glucocorticoids with an equivalent dose of more than 5mg dexamethasone 5 days prior to initial administration.
- •Patients have spinal cord compression caused by tumor.
- •Clinically severe gastrointestinal dysfunction may affect the ingestion, transport or absorption of the study drugs.
- •Cardiac function and disease are consistent with the following:
- •Corrected QT interval(QTc)> 470 milliseconds from 3 electrocardiograms (ECGs);
- •Any clinically important abnormalities in rhythm;
- •Any factors that increase the risk of QTc prolongation;
- •Left ventricular ejection fraction (LVEF) <50%.
- •Active human immunodeficiency virus (HIV), syphilis, hepatitis c virus (HCV) or hepatitis b virus (HBV) infection, with the exception of asymptomatic chronic hepatitis b or hepatitis c carriers.
- •Previous history of interstitial lung disease(ILD)#drug-induced ILD or radiation pneumonitis require steroid treatment, or any evidence of clinically active ILD diseases.
- •Previous allogeneic bone marrow transplant.
- •Pregnant or lactating women.
- •Any other disease or medical condition that is unstable or may affect the safety or study compliance.
- •Hypersensitivity to TY-9591 or similar compounds or excipients.
研究组 & 干预措施
TY-9591 Tablets
Experimental
TY-9591 Tablets 160mg/d
干预措施: TY-9591 Tablets (Drug)
结局指标
主要结局
Extracranial Overall Response Rate (eORR)
时间窗: 13 months.
eORR is defined as the proportion of patients with a best extracranial response of complete response (CR) or partial response (PR) during the study treatment
Intracranial Overall Response Rate (iORR)
时间窗: 13 months.
iORR is defined as the proportion of patients with a best intracranial response of complete response (CR) or partial response (PR) during the study treatment
次要结局
- Intracranial Median Progression Free Survival (iPFS)(13 months.)
- Overall Survival (OS)(From the date of first dose until the date of death from any cause or loss to follow-up, whichever comes first, assessed up to 100 months)
- Objective Response Rate (ORR)(13 months.)
- Disease Control Rate (DCR)(13 months.)
- Duration of Response (DoR)(13 months.)
- Median Progression Free Survival (PFS)(13 months.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Non-Small-Cell Lung CancerNCT05255406Fudan University62
招募中
2 期
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesEGFR Activating MutationBrain MetastasesNSCLCNCT05948813TYK Medicines, Inc420
已完成
2 期
AUY922 in Patient With Stage IV NSCLCNon-small Cell Lung Cancer (NSCLC)NCT01922583National Taiwan University Hospital31
尚未招募
2 期
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLCNSCLCNCT06672068TYK Medicines, Inc60
Unknown
2 期
Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMSNon-Small Cell Lung Cancer With EGFR T790M MutationWith Brain and/or Leptomeningeal MetastasisFailed Tyrosine Kinase InhibitorsNCT03257124Samsung Medical Center80